Chao Chen, Yangyang Zhang, Qianqian Liu, Meiding Wang, Su Mou, Jun Luo, Guo Zhou
{"title":"Impact of real-time contrast-enhanced ultrasound on thyroid function in microwave ablation treatment of thyroid tumors.","authors":"Chao Chen, Yangyang Zhang, Qianqian Liu, Meiding Wang, Su Mou, Jun Luo, Guo Zhou","doi":"10.62347/OIUD6634","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the impact of contrast-enhanced ultrasound on the efficacy of microwave ablation in the treatment of benign thyroid tumors, as well as its effect on thyroid function, to assess its application value.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 60 patients with benign thyroid nodules treated at Sichuan Provincial People's Hospital from January 2021 to December 2021. All patients underwent microwave ablation. Based on the intraoperative assessment of the ablation effect, they were divided into a contrast-enhanced ultrasound group (n=34) and a conventional ultrasound group (n=26). Postoperatively, the treatment outcomes were classified into complete ablation or the presence of residual nodules. We also assessed the recurrence rate one year after treatment, along with inflammatory factors, stress response indicators, and effects on thyroid function.</p><p><strong>Results: </strong>The complete ablation rate for thyroid nodules in the contrast-enhanced ultrasound group was significantly higher than that in the conventional ultrasound group (P<0.05). Intraoperative measurements revealed lower ablated nodule volumes, bleeding volumes, and in situ replacement rates in the contrast-enhanced ultrasound group, with statistically significant differences (P<0.05). Preoperative thyroid function hormone indicators, inflammatory factors and stress response indicators did not significantly differ between the two groups. Postoperatively, both groups had lower levels of free triiodothyronine (FT3) and free thyroxine (FT4), along with higher levels of thyroid-stimulating hormone (TSH), white blood cells (WBC), serum C-reactive protein (CRP), interleukin-6 (IL-6), norepinephrine (NE), epinephrine (E), and cortisol (Cor) compared to preoperative levels. However, the contrast-enhanced ultrasound group demonstrated higher FT3 and FT4 levels and lower WBC, serum CRP, IL-6, NE, E, Cor and TSH levels than the conventional ultrasound group, with statistically significant differences (all P<0.05). No statistically significant differences in complication rates were observed between the two groups.</p><p><strong>Conclusion: </strong>Contrast-enhanced ultrasound in microwave ablation for benign thyroid nodules can improve the complete ablation rate, reduce recurrence, and have a minimal impact on thyroid function, without increasing complication rates. It is recommended for clinical use.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 1","pages":"32-41"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/OIUD6634","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Impact of real-time contrast-enhanced ultrasound on thyroid function in microwave ablation treatment of thyroid tumors.
Objective: To investigate the impact of contrast-enhanced ultrasound on the efficacy of microwave ablation in the treatment of benign thyroid tumors, as well as its effect on thyroid function, to assess its application value.
Methods: We retrospectively analyzed data from 60 patients with benign thyroid nodules treated at Sichuan Provincial People's Hospital from January 2021 to December 2021. All patients underwent microwave ablation. Based on the intraoperative assessment of the ablation effect, they were divided into a contrast-enhanced ultrasound group (n=34) and a conventional ultrasound group (n=26). Postoperatively, the treatment outcomes were classified into complete ablation or the presence of residual nodules. We also assessed the recurrence rate one year after treatment, along with inflammatory factors, stress response indicators, and effects on thyroid function.
Results: The complete ablation rate for thyroid nodules in the contrast-enhanced ultrasound group was significantly higher than that in the conventional ultrasound group (P<0.05). Intraoperative measurements revealed lower ablated nodule volumes, bleeding volumes, and in situ replacement rates in the contrast-enhanced ultrasound group, with statistically significant differences (P<0.05). Preoperative thyroid function hormone indicators, inflammatory factors and stress response indicators did not significantly differ between the two groups. Postoperatively, both groups had lower levels of free triiodothyronine (FT3) and free thyroxine (FT4), along with higher levels of thyroid-stimulating hormone (TSH), white blood cells (WBC), serum C-reactive protein (CRP), interleukin-6 (IL-6), norepinephrine (NE), epinephrine (E), and cortisol (Cor) compared to preoperative levels. However, the contrast-enhanced ultrasound group demonstrated higher FT3 and FT4 levels and lower WBC, serum CRP, IL-6, NE, E, Cor and TSH levels than the conventional ultrasound group, with statistically significant differences (all P<0.05). No statistically significant differences in complication rates were observed between the two groups.
Conclusion: Contrast-enhanced ultrasound in microwave ablation for benign thyroid nodules can improve the complete ablation rate, reduce recurrence, and have a minimal impact on thyroid function, without increasing complication rates. It is recommended for clinical use.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.